Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025

Larimar Therapeutics, Inc.

2024-Q3 EPS reported -$0.86

Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
Cash, cash equivalents and marketable securities $203.7M as of Sep 30, 2024; projected runway into 2026.
Nomlabofusp program update in mid-Dec with safety, PK, frataxin data from 25 mg daily OLE study.
PK run-in study in adolescents on track by year-end 2024; global confirmatory study planned mid-2025.
BLA submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.